INTRODUCTION
Porcine reproductive and respiratory syndrome virus (PRRSV) was first isolated in the early 1990s and belongs to the Arteriviridae viral family in the genus Arterivirus, order Nidovirales [1] . The viral genome consists of a positive single-stranded RNA molecule of approximately 15 kb in length, composed of nine open reading frames [2] [3] [4] . The ORFs 5 to 7 encode the three major structural proteins of virions which are the envelope glycoprotein GP5 (25) (26) , the non-glycosylated membrane protein M (18-19 kDa) and the nucleocapsid protein N (14-15 kDa) [5] . These PRRSV structural proteins are closely associated, GP5 and M proteins being associated in the form of heterodimers [5] .
Circulating antibodies in PRRSV-infected pigs responsible for viral neutralization in cell cultures are mainly directed against GP5 [6] . Immunization of mice with Escherichia coli-expressed GST-ORF5 recombinant fusion protein, as well as with purified PRRSV, induced specific anti-GP5 neutralizing monoclonal antibodies [7] . Furthermore, genetic immunization of pigs with plasmidic DNA expressing the ORF5 gene triggered the production of transient and low titers of neutralizing antibodies to PRRSV and conferred protection against development of clinical disease and lung lesions but were not sufficient to inhibit virus persistence and shedding in the respiratory tract of PRRSV challenged pigs [8] . On the other hand, when the E. coli-expressed GST-ORF5 recombinant fusion protein was used as immunogen prior to challenge with pathogenic virus, the disease was more severe, despite the development of high titers of non-neutralizing antibodies to GP5 thus suggesting the involvement of a possible antibodydependent enhancement phenomenon [8] . These findings suggest also that the amounts of GP5 synthesized in the infected cells, as well as conformation of the protein which may be influenced by the type of oligosaccharide side chains present on the molecule, are apparently crucial to trigger an effective humoral immune response to PRRSV. Since a correlation may exist amongst protection, clinical course of the disease, and seroneutralizing antibody titers [9, 10] , the present study was designed to increase the efficacy of genetic immunization against antigenic determinants of GP5.
Live human adenovirus type 5 vector (hAdV) has been shown to be an excellent delivery system for vaccine immunogens [11] . Both replication-defective and replication-competent hAdV have been used as 4 efficient recombinant vaccines [12] but for biosafety consideration, a replication-defective hAdV is considered to be more suitable for vaccine development. Even if E1 deleted hAdV is unable to replicate in vivo, it is able to induce a protective immune response in different species including swine [13] . A synthetic ORF5 gene (synORF5) was then generated in which codon usage was optimized for expression in mammalian cells as previously reported for HIV gp120 [14] . It was demonstrated that synORF5 gene carried by a tetracycline-controlled hAdV is expressed at higher levels than that of the wild-type ORF5 gene (wtORF5) and triggers production of higher titers of neutralizing antibodies which appeared earlier in sera of challenged pigs. This suggests that efficacy of DNA vaccines or recombinant viral vaccines may be improved by optimization of translational process of the GP5 protein of PRRSV.
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MATERIAL AND METHODS
Viruses and cells.
The Québec cytopathogenic IAF-Klop strain of PRRSV was propagated in MARC-145 cells, as previously described [15] . Ad/CMVlacZ [16] , a replication-defective E1-and E3-deleted hAdV5, as well as generated hAdVs, were propagated in 293 cells (ATCC CRL-1573) to permit replication of replicationdefective hAdVs. AdCMV/tTA permits the constitutive expression of the tetracycline transactivator (tTA) in infected cells using the constitutive CMV immediate-early promoter/enhancer. The tTA is essential to allow expression in hAdV-infected cells of the transgenes which have been cloned downstream and under the control of the tetracycline-regulatable (TR5) promoter. Doxycycline, an analogue of tetracycline, was used at a concentration of 1 µg/ml to inhibit the transgene expression in hAdV-infected cells [16] . The 293 Tet-On cells (Clontech Inc., Palo Alto, CA) are 293 transformed cells that constitutively express the reverse tetracycline transactivator (rtTA). These cells were cultivated in the presence of 1 µg/ml of doxycycline to enhance expression of the transgene placed under the control of the TR5 promoter [16] .
Antiserum.
Rabbit monospecific hyperimmune serum (α5) to E. coli-expressed ORF5 product of the IAF-Klop PRRSV reference strain was obtained from previous studies [5] .
Construction of PRRSV synthetic ORF5 gene.
The codons most frequently used by mammalian cells were used to construct a synthetic ORF5 (synORF5) gene according to Haas et al., (1996) [17]. The DNA template used to construct synORF5 was based on the ORF5 sequence of the IAF-Klop strain of PRRSV (Genbank accession number U64928).
The synORF5 gene was assembled by single overlap PCR, as described by Holler et al., (1993) [18] .
Generation of recombinant replication-defective hAdVs. The synORF5 and wtORF5 genes were inserted in the Bgl II site of the adenovirus transfer vectors pAdTR5/DC/GFPq so they would be under the control of the TR5 promoter [16] . To facilitate screening and selection of the recombinant hAdVs, the shuttle vector used in these experiments, contains the green fluorescent protein (GFPq) reporter gene downstream the multiple cloning site under the control of an IRES [19] .The recombinant plasmids were rescued into the genome of Ad/CMVlacZ, a replication-defective E1-and E3-deleted hAdVs, by homologous recombination in 293 cells, as described elsewhere [15] . The GP5-expressing hAdVs (hAdV/wtORF5 and hAdV/synORF5) were subjected to three consecutive rounds of plaque purification, then selected viral clones were amplified as previously described [15] . Infectivity titers of the hAdVs were determined by calculation of the plaque forming units (PFU/ml) on 293 cell monolayers, as previously described [15] .
Indirect Immunofluorescence assay.
The indirect immunofluorescence (IIF) assay was used to detect the expression of the GP5 in hAdVs MARC-145 infected cells. Following an incubation period of 24 and 48 h post-infection, those hAdVs infected cells were fixed with a 80% cold acetone solution for 20 min at 4 o C and the IIF was done using a 1/200 dilution of the α5 serum as previously described [20] .
Western blotting experiments.
Sucrose gradient purified-PRRSV was prepared in LB-2 lysis buffer [5] , denatured by boiling in the presence of 5% (V/V) β-mercaptoethanol, subjected to 12% SDS-PAGE and electrotransferred onto nitrocellulose membranes as previously described [5, 20] . Reactivity of pig sera (dilution 1/50) was tested and the α5 serum was used as a positive control.
Metabolic labeling and immunoprecipitation of PRRSV native or recombinant proteins.
Radiolabeling with [ Tet-On cells infected with hAdVs, was carried out essentially as previously described [15] . Aliquots of 10 7 cpm of clarified radiolabeled lysates of PRRSV-infected, hAdVs-infected or mock-infected cells were incubated with α5 serum and processed as previously described [15] .
Animal group description and immunization schedule.
Nine crossbred F1 (Landrace x Yorkshire) castrated specific pathogen-free (SPF) piglets of 4 to 5 weeks of age were randomly divided into one control group and two experimental groups (3 piglets/group). The animals were fed with commercial feed (without tetracycline supplement) and water ad libitum. Piglets were given two injections of different mixtures of hAdVs, 32 days apart. Each pig of the first group received 100 µl of a suspension containing 10 9 PFU of hAdV/wtORF5 mixed with 5 X 10 9 PFU of AdCMV/tTA. Each pig of the second group received a suspension mix of 100 µl of 10 9 PFU of hAdV/synORF5 and 5 X 10 9 PFU of AdCMV/tTA. The third group which was used as the control group was given a volume of 100 µl of a suspension containing 5 X 10 9 PFU of AdCMV/tTA alone. These different viral suspensions were prepared in PBS containing 0,02% of the poloxamer SP1017 [21] . The viral suspensions were injected intradermally under the right ear using a 30-gauge needle. The animals were challenged intranasally at day 60 with a dose of 10 5 TCID50 of the IAF-Klop strain of PRRSV in 5 ml of clarified cell culture supernatant fluid. Pigs were bled at days 0, 10 and 21 post-challenge.
Virus neutralization and serological tests.
Pig sera were tested for the presence of anti-GP5 specific antibodies by virus neutralization (VN), IIF, ELISA and WB tests. The VN tests were performed in triplicates with 100 TCID50 of the virus/well as previously described [22] . To monitor humoral immune response following challenging of vaccinated pigs, an IIF using PRRSV infected MARC-145 cells as well as a competitive ELISA for detection of antibodies to PRRSV using recombinant E. coli-expressed N protein as antigen and a commercial indirect ELISA (IDEXX) for detection of anti-PRRSV antibodies were used as previously described [23] .
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Construction of a synthetic ORF5 gene based on optimal codon usage.
The synORF5 sequence contains a total of 134 nt substitutions compared to the wtORF5, resulting in an overall 77,8 % (469/603) identity at the nt level, but deduced aa sequences from both wtORF5 and synORF5 are 100 % identical (data not shown). Thus, a new gene coding for the major GP5 envelope glycoprotein of a North American PRRSV, the IAF-Klop strain, was successfully created, to which EMBL/Genbank accession number AY184209 has been assigned.
Generation of recombinant replication-defective adenoviral vectors.
Our previous results indicate that to be able to obtain replication-defective hAdVs expressing the ORF5 gene, the ORF5 expression has to be regulated because the GP5 induced cell death by apoptosis and appeared highly toxic per se and subsequently prevent the construction of recombinant hAdV [15] . This is why a regulatable promoter has been used for the construction of hAdVs. Notheworthy, coinfection of the tTA expressing hAdV (AdCMV/tTA) with hAdVs expressing the ORF5 under the control of the TR5 promoter (hAdV/wtORF5 or hAdV/synORF5) was essential for efficient expression of the PRRSV recombinant protein in MARC-145 cells, as well as in 293 cells.
Expression level of the wtORF5 and synORF5.
Following infection at a moi of 100 PFU per cell, until 70 h pi, the intensity of the reporter protein (GFP) fluorescence was higher in cells infected with rec hAdVs expressing the synORF5 gene than those expressing the wtORF5 gene (data not shown). In agreement with the above findings, expression of the GP5 was also higher in MARC-145 cells infected with hAdV/synORF5 than those infected with hAdV/wtORF5, the intensity of the cytoplasmic fluorescence obtained by IIF using the α5 antibodies being optimal at 48 h pi (figure 1). Accordingly, a significant higher cellular destruction was observed in MARC-145 cells following infection with hAdV/synORF5 due to the higher expression level of the GP5 (data not shown). Since MARC-145 cells are not permissive to replication of deficient (E1 deleted) recombinant hAdVs, this level of cellular degeneration was rather attributed to the toxicity of the GP5.
In order to correlate data obtained by IIF with levels of GP5 synthesis, RIPA experiments were conducted with lysates of 293 rtTA cells infected with either hAdV/wtORF5 or hAdV/synORF5. As shown in figure 2a figure 3 and table 1) . Also, all hAdV vaccinated groups developed viremia (as tested by RT-PCR) at day 10 post-challenge and one pig in each group still had viremia at day 21 post-challenge (data not shown).
DISCUSSION
We believe that the increase of gene level expression observed in the case of synORF5 compared to the wtORF5 is most likely a purely translational effect, as previously described with HIV-1 [14, 17] , but still to be proven. Overall, the nt sequence of the synORF5 showed 78 % identity with the wtORF5 nt sequence of the IAF-Klop strain and as 57 % nt identity with the reference European LV strain in comparison to 63% nt identity between the wtORF5 of IAF-Klop strain and LV strain. Nevertheless, deduced aa sequences from both wtORF5 and synORF5 genes of the North American IAF-Klop strain were 100% identical, but displayed only 52 % identity with that of the European strain.
The data presented here clearly support that codon usage can play an important role in determining the expression efficiency in a mammalian cell context as previously described [24] . Also, in regards of improving the immune response, the vaccination of pigs with non-replicative and inducible hAdVs carrying synthetic ORF5 gene with optimized codon usage at least resulted in the establishment of an enhanced immunological memory to antigenic determinants of GP5, including those involved in the production of neutralizing antibodies. Indeed, following challenge, the hAdV/synORF5-vaccinated pigs developed a higher specific humoral immune response against GP5, including VN antibodies, than any other vaccinated pigs.
Also, the humoral immune response was detected much earlier, being as soon as 10 days post-challenge, indicating that they underwent an earlier anamnestic immune response. The VN antibodies response detected at 10 days post-challenge was the specific consequence of prior immunization with hAdV/synORF5 since normally, VN antibodies are detected after only 3 to 4 weeks in SPF pigs experimentally-or naturallyinfected with PRRSV [10, 20] . The higher reactivity to GP5, as well as the higher VN activity of pigs sera that have been vaccinated either with hAdV/wtORF5 or hAdV/synORF5 is in agreement with previous findings indicating that GP5 is the primary structural glycoprotein of PRRSV involved in virus neutralization activity [6, 7, 25] . Even if high titers of VN antibodies appeared at day 10 post-challenge, the viremia could not be prevented (data not shown) as previously observed [10, 26, 27] . Nevertheless, one report has demonstrated the protective effect of neutralizing antibodies and their potential to prevent viremia [9] .
One explanation for the absence of specific immune response prior to challenge inoculation may be the fact that two recombinant hAdVs have to be injected to assure the expression of the transgene. In vivo, there is no guaranty that the same cell can be infected by the two hAdVs, thereby reducing the transgene expression compared to the experiments conducted with cell cultures.
A possible explanation for the enhanced immune response in challenged pigs might be the increase in CpG motifs in the synthetic gene that was administered [28] which however appears to be less important than in the case of the syngp120 previously described for HIV-1 [14] . In the last few years, several groups have demonstrated that DNA containing unmethylated CpG motifs is more efficient to trigger B-cell activation [29, 30] and also contribute to the immunogenicity of gene vaccines [28, 31] .
Additional experiments are needed to determine if DNA immunisation with synORF5 also improves the cellular immune response, as described earlier for HIV-1 [14] . Further improvement might also be achieved with cytokine or cytokine-plasmid adjuvants [32] [33] [34] . Alternatively, it might be useful to increase the number of potential epitopes by coinjection of DNA plasmids carrying other PRRSV genes, since it has been previously described that epitopes of the GP4 of European strains are also involved in virus neutralisation [35] , and that the M protein is the one mainly involved in the cellular immune response or cellular hypersensibility [36] . Moreover, expression of the two major envelope proteins of EAV as heterodimers was found recently necessary for induction of neutralizing antibodies in mice and horses immunized with recombinant Venezuelan equine encephalitis virus replicon particles [37, 38] , but this remains to be demonstrated in the case of PRRSV. Nevertheless, our major goal in the very near future is the generation of a hAdV carrying both the synORF5 gene of PRRSV under the control of an inducible promotor for control of the toxicity and the transactivator gene to eliminate the need of using two hAdVs, as described in the present study, and subsequently will improve the transgene expression in vivo. FIGURES LEGENDS 7 cpm) with α5 serum were processed as previously described [15] . Western blot strips were prepared using sucrose-gradient purified PRRSV (IAF-Klop strain) as
antigen. The reactivity profiles of pig sera collected 10 days and 21 days post-challenge are illustrated in A and B, respectively. The positive control (+) corresponds to the reactivity of the α5 serum with the sucrose gradient purified virus.
